Abstract
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have